(via NewsDirect)
AdAlta Ltd (ASX:1AD) managing director Dr Tim Oldham tells Proactive the company is seeking an early return to clinical trials of its lead asset, AD-214, with a $3.5 million non-renounceable rights offer. AdAlta has already received commitments from investors for $2.49 million of the target amount.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases